A boxed warning concerning lactic acidosis was added to the label for glyburide-metformin hydrochloride, effective 2026-07-15. This significant label revision highlights the severe risks associated with metformin, a component of the drug, including postmarketing cases that have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias.
Background
The combination drug glyburide-metformin hydrochloride received a boxed warning concerning lactic acidosis. This warning, issued by the FDA, specifically addresses risks associated with the metformin component of the medication. The label update highlights that postmarketing cases of metformin-associated lactic acidosis have resulted in severe outcomes, including death, hypothermia, hypotension, and resistant bradyarrhythmias.
What this means
The addition of a boxed warning for lactic acidosis to the glyburide-metformin hydrochloride label underscores the critical importance of recognizing and managing this severe adverse event. This FDA-mandated warning serves to prominently communicate the serious risks, including death, hypothermia, hypotension, and resistant bradyarrhythmias, associated with metformin-containing products like glyburide-metformin hydrochloride. Clinicians are now formally alerted to these postmarketing findings, necessitating a heightened awareness when prescribing and monitoring patients. Researchers may find this update relevant for ongoing safety studies and risk assessment. Patient advocates can leverage this information to ensure individuals taking glyburide-metformin hydrochloride are fully informed about the potential for lactic acidosis and its serious manifestations.
Source
This information was sourced from the FDA, detailing a label revision for glyburide-metformin hydrochloride effective 2026-07-15. The updated label is available on dailymed.nlm.nih.gov.